Formal written minutes from the U.S. FDA confirms no major concerns identified for the planned Phase 3 PANDA study of [68Ga]Ga-PentixaFor in treatment-resistant hypertension and Primary AldosteronismT ...
Formal written minutes from the U.S. FDA confirms no major concerns identified for the planned Phase 3 PANDA study of ...
An announcement from Mineralys Therapeutics, Inc. ( ($MLYS) ) is now available. On January 6, 2026, Mineralys Therapeutics provided a corporate ...
Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease ...
Crinetics Pharmaceuticals reported positive topline results from Phase 2 studies of atumelnant for CAH and ACTH-dependent Cushing's syndrome.
AstraZeneca notes baxdrostat shows reduction in systolic blood pressure in phase III of uncontrolled or resistant hypertension: Our Bureau, Bengaluru Monday, January 5, 2026, 18:0 ...
Why cutting back on salt is important—but going too low may disrupt blood pressure, electrolytes and overall health.
Why cutting back on salt is important—but going too low may disrupt blood pressure, electrolytes and overall health.
The authors conclude that lorundrostat shows promise as an effective blood pressure–lowering therapy for patients with ...
The epidemiology of hypertension in India has undergone a malignant shift, moving from a disease of the elderly to a ...
Detailed price information for Cspc Pharmaceuticals Group Ltd (CHJTF) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback